1st Cir. Affirms Dismissal of Qui Tam Case Against Takeda Relating to Actos, Prevacid

BOSTON — The relator in a qui tam case against Takeda Pharmaceutical Company Ltd. failed to establish that the drug maker’s alleged failure to disclose the risks posed by four of its drugs, including Actos, resulted in the submission of false claims for Medicare and Medicaid reimbursement, a federal appeals court has affirmed.

On Dec. 6, the 1st Circuit U.S. Court of Appeals rejected Ge’s theories to support her assertion that all claims submitted for the drugs were rendered false by Takeda's alleged misconduct. The court found the theories were waived because they were not properly presented to the trial …